To Reduce Patient Harm
Development of drugs and therapeutics is both risky and costly. Numerous drugs have been withdrawn from the market because of adverse clinical side effects and risks to patients. Cardiotoxicity is a common leading cause, even for drugs not for the heart. As an example, in the Cardiac Arrhythmia Suppression Trial (CAST) conducted between 1986 and 1998, several “anti-arrhythmics” were found to unexpectedly increase mortality by causing lethal arrhythmias after testing in over 1700 patients. With Novoheart’s proprietary technology, the pro-arrhythmic properties of failed CAST drugs such as flecainide could be readily detected, with assessed risks comparable to what was clinically observed (Shum et al 2016, Advanced Materials).